Cancer Immunology, Immunotherapy

, 60:1509

Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma

Authors

  • Adam J. Bograd
    • Division of Thoracic SurgeryMemorial Sloan-Kettering Cancer Center
    • Center for Cell EngineeringMemorial Sloan-Kettering Cancer Center
  • Kei Suzuki
    • Division of Thoracic SurgeryMemorial Sloan-Kettering Cancer Center
  • Eva Vertes
    • Division of Thoracic SurgeryMemorial Sloan-Kettering Cancer Center
    • Center for Cell EngineeringMemorial Sloan-Kettering Cancer Center
  • Christos Colovos
    • Division of Thoracic SurgeryMemorial Sloan-Kettering Cancer Center
    • Center for Cell EngineeringMemorial Sloan-Kettering Cancer Center
  • Eduardo A. Morales
    • Division of Thoracic SurgeryMemorial Sloan-Kettering Cancer Center
  • Michel Sadelain
    • Center for Cell EngineeringMemorial Sloan-Kettering Cancer Center
    • Division of Thoracic SurgeryMemorial Sloan-Kettering Cancer Center
    • Center for Cell EngineeringMemorial Sloan-Kettering Cancer Center
Review

DOI: 10.1007/s00262-011-1103-6

Cite this article as:
Bograd, A.J., Suzuki, K., Vertes, E. et al. Cancer Immunol Immunother (2011) 60: 1509. doi:10.1007/s00262-011-1103-6

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive, primary pleural malignancy with poor prognosis, hypothesized to originate from a chronic inflammatory state within the pleura. Similar to what has been observed in other solid tumors (melanoma, ovarian and colorectal cancer), clinical and pre-clinical MPM investigations have correlated anti-tumor immune responses with improved survival. As such, a better understanding of the complex MPM tumor microenvironment is imperative in strategizing successful immunotherapies. Herein, we review the immune responses vital to the development and progression of MPM, as well as assess the role of immunomodulatory therapies, highlighting recent pre-clinical and clinical immunotherapy investigations.

Keywords

MesotheliomaImmune response to cancerImmunotherapyImmunomodulationTumor antigens

Copyright information

© Springer-Verlag 2011